NEW HAVEN, Conn., Dec. 8, 2017 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the presentation of new preclinical data for its novel oral estrogen receptor (ER) alpha PROTAC program…
News
- Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio ...
- 3 Things In Biotech You Should Learn Today: December 8, 2017
News: NVS presented the findings from MONALEESA-7 at the San Antonio Breast Cancer Symposium, which explored the use of ribociclib (branded Kisqali) and endocrine therapy in premenopausal women with metastatic hormone-positive breast cancer. The findings were stellar, with a substantial…
- Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines ...
... biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines to PCM-075, its highly selective Polo-like kinase 1 (PLK1) Inhibitor, will be featured as a Poster Presentation at the 40th San Antonio Breast Cancer…
- Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in ...
BOTHELL, WA, USA I December 7, 2017 I Seattle Genetics, Inc. (NASDAQ: SGEN) today announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium…
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
LOS ANGELES, CA, USA I December 6, 2017 I Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in…